Nevro Corp. (NYSE:NVRO) Director Wilfred E. Jaeger sold 52,520 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $86.11, for a total transaction of $4,522,497.20. Following the transaction, the director now owns 1,518 shares of the company’s stock, valued at $130,714.98. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Wilfred E. Jaeger also recently made the following trade(s):

  • On Tuesday, August 15th, Wilfred E. Jaeger sold 29,665 shares of Nevro Corp. stock. The shares were sold at an average price of $82.54, for a total transaction of $2,448,549.10.
  • On Monday, August 14th, Wilfred E. Jaeger sold 25,255 shares of Nevro Corp. stock. The shares were sold at an average price of $82.40, for a total transaction of $2,081,012.00.
  • On Wednesday, August 16th, Wilfred E. Jaeger sold 79,657 shares of Nevro Corp. stock. The shares were sold at an average price of $82.74, for a total transaction of $6,590,820.18.

Nevro Corp. (NVRO) traded up 0.07% during mid-day trading on Friday, hitting $86.42. 183,918 shares of the stock were exchanged. The company has a 50-day moving average of $84.55 and a 200-day moving average of $85.06. Nevro Corp. has a 52 week low of $65.82 and a 52 week high of $106.93. The stock’s market capitalization is $2.54 billion.

Nevro Corp. (NYSE:NVRO) last issued its earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.11. The firm had revenue of $78.02 million during the quarter, compared to analyst estimates of $77.75 million. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The firm’s revenue was up 40.8% compared to the same quarter last year. During the same period last year, the business earned ($0.31) EPS. On average, equities analysts predict that Nevro Corp. will post ($1.16) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2017/08/25/nevro-corp-nvro-director-wilfred-e-jaeger-sells-52520-shares.html.

A number of research analysts have recently commented on NVRO shares. Northland Securities set a $96.00 price target on shares of Nevro Corp. and gave the company a “buy” rating in a research report on Thursday, June 15th. Canaccord Genuity restated a “buy” rating and set a $120.00 price target on shares of Nevro Corp. in a research report on Wednesday, July 5th. Zacks Investment Research upgraded shares of Nevro Corp. from a “strong sell” rating to a “buy” rating and set a $96.00 price target for the company in a research report on Wednesday, August 2nd. BidaskClub upgraded shares of Nevro Corp. from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. Finally, B. Riley downgraded shares of Nevro Corp. from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $108.00 to $85.00 in a report on Tuesday, May 9th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $100.57.

A number of hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Nevro Corp. during the fourth quarter valued at $750,000. Teachers Advisors LLC boosted its stake in shares of Nevro Corp. by 11.3% in the fourth quarter. Teachers Advisors LLC now owns 42,735 shares of the medical equipment provider’s stock valued at $3,105,000 after buying an additional 4,333 shares during the period. Bank of Montreal Can boosted its stake in shares of Nevro Corp. by 79.7% in the first quarter. Bank of Montreal Can now owns 9,653 shares of the medical equipment provider’s stock valued at $904,000 after buying an additional 4,281 shares during the period. First Mercantile Trust Co. boosted its stake in shares of Nevro Corp. by 37.3% in the first quarter. First Mercantile Trust Co. now owns 14,049 shares of the medical equipment provider’s stock valued at $1,317,000 after buying an additional 3,820 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of Nevro Corp. by 8.5% in the first quarter. Russell Investments Group Ltd. now owns 73,402 shares of the medical equipment provider’s stock valued at $6,875,000 after buying an additional 5,767 shares during the period.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.